Oncolytics at Fresh 52-Week High on Drug Results - InvestingChannel

Oncolytics at Fresh 52-Week High on Drug Results

Oncolytics Biotech Inc. (T.ONC) hit a new 52-week high of $2.50 Thursday. Oncolytics announced updated results from the phase 1/2 GOBLET study’s first-line advanced/metastatic pancreatic ductal adenocarcinoma (PDAC) cohort. Patients in this cohort are treated with the combination of pelareorep, Roche’s anti-PD-L1 checkpoint inhibitor atezolizumab, and the chemotherapeutic agents gemcitabine and nab-paclitaxel.

Alamos Gold Inc. (T.AGI) hit a new 52-week high of $11.85 Thursday. No news stories available today.

Alimentation Couche-Tard Inc. (T.ATD) hit a new 52-week high of $62.38 Thursday. No news stories available today.

CES Energy Solutions Corp. (T.CEU) hit a new 52-week high of $3.17 Thursday. No news stories available today.

Enterprise Group Inc. (T.E) hit a new 52-week high of 41.5 cents Thursday. No news stories available today.

Metro Inc. (T.MRU) hit a new 52-week high of $73.29 Thursday. No news stories available today.

Pet Valu Holdings Ltd. (T.PET) hit a new 52-week high of $41.74 Thursday. No news stories available today.

Shawcor Ltd. (T.SCL) hit a new 52-week high of $10.10 Thursday. No news stories available today.

Stella-Jones Inc. (T.SJ) hit a new 52-week high of $44.37 Thursday.

Uni-Select Inc. (T.UNS) hit a new 52-week high of $41.74 Thursday. No news stories available today.

Related posts

Advisors in Focus- January 6, 2021

Gavin Maguire

Advisors in Focus- February 15, 2021

Gavin Maguire

Advisors in Focus- February 22, 2021

Gavin Maguire

Advisors in Focus- February 28, 2021

Gavin Maguire

Advisors in Focus- March 18, 2021

Gavin Maguire

Advisors in Focus- March 21, 2021

Gavin Maguire